Dr. Rathmell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
9000 Rockville Pike
Bethesda, MD 20892Phone+1 240-781-3300
Summary
- Dr. W. Kimryn Rathmell is the Director of the National Cancer Institute, United States of America, and was appointed by Joseph Biden, Jr. on December 18, 2023. She is an oncologist who previously practiced in Nashville, TN and was affiliated with Vanderbilt University Medical Center, where she served as the Chair of Medicine. She received her medical degree from Stanford University School of Medicine and has been in practice 20+ years. She specializes in genitourinary oncology and genetic oncology and is experienced in urologic oncology, internal medicine, medical oncology, and hereditary risk associated kidney neoplasms.
Education & Training
- Vanderbilt UniversityMMHC, Masters of Management in Health Care, 2021 - 2022
- University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2000 - 2004
- University of Pennsylvania Health SystemResidency, Internal Medicine, 1999 - 2002
- University of ChicagoInternship, Internal Medicine, 1998 - 1999
- Stanford University School of MedicineClass of 1998
- Stanford UniversityPh.D., Biophysics, 1993 - 1996
- University of Northern IowaBS, Biology, 1987 - 1991
- University of Northern IowaBA, Chemistry, 1987 - 1991
Certifications & Licensure
- TN State Medical License 2015 - 2025
- KY State Medical License 2021 - 2024
- IA State Medical License 2021 - 2023
- WI State Medical License 2021 - 2023
- AL State Medical License 2020 - 2022
- MS State Medical License 2021 - 2022
- NC State Medical License 2003 - 2016
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- American Acadamy of Arts and Sciences 2023
- National Academy of Medicine 2022
- Alpha Omega Alpha 2013
- Join now to see all
Clinical Trials
- Sorafenib in Treating Patients Undergoing Surgery for Stage II, Stage III, or Stage IV Kidney Cancer Start of enrollment: 2006 Nov 01
Publications & Presentations
PubMed
- 2 citationsSubset-specific mitochondrial stress and DNA damage shape T cell responses to fever and inflammation.Darren R Heintzman, Rachael C Sinard, Emilie L Fisher, Xiang Ye, Andrew R Patterson
Science Immunology. 2024-09-20 - Author Correction: Obesity induces PD-1 on macrophages to suppress anti-tumour immunity.Jackie E Bader, Melissa M Wolf, Gian Luca Lupica-Tondo, Matthew Z Madden, Bradley I Reinfeld
Nature. 2024-07-01 - 1 citationsA Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).Edward Maldonado, W Kimryn Rathmell, Geoffrey I Shapiro, Naoko Takebe, Jordi Rodon
Cancer Research Communications. 2024-07-01
Journal Articles
- Publisher Correction: Clinical Activity and Molecular Correlates of Response to Atezolizumab Alone or in Combination with Bevacizumab Versus Sunitinib in Renal Cell Ca...Michael B Atkins, Mario Sznol, Robert J Motzer, Richard W Joseph, Thomas Hutson, John Hainsworth, W Kimryn Rathmell, Brian I Rini, David F McDermott, Toni K Choueiri, ..., Nature
- VHL Substrate Transcription Factor ZHX2 as an Oncogenic Driver in Clear Cell Renal Cell CarcinomaEric Jonasch, Xian Chen, William Y Kim, W Kimryn Rathmell, Science Magazine
- Epigenetic Modifiers: Activities in Renal Cell CarcinomaW. Kimryn Rathmell, MD, Nature
- Join now to see all
Books/Book Chapters
Lectures
- Renal Cell Carcinoma.Nashville, TN - 1/1/2016
- Translational Research at the Bioinformatic Edge.Schloss Dagstuhl, Wadern, Germany - 1/1/2016
- Renal Medullary CarcinomaNashville, TN - 1/1/2016
- Join now to see all
Other
- Tumor Genomics ProgramRathmell, WK
http://university.asco.org/tumor-genomics-program
ASCO University. - 1/1/2014 - Comment on autophagy related to VHL gene as a strategy to develop cancer treatmentsRathmell, WK, NPR Morning Edition.
1/1/2008 - mTOR: An Emerging Pathway in CancerRathmell, WK. and Shaw R., Novartis Internal Training Module.
1/1/2008 - Join now to see all
Authored Content
- ASCO Afterthoughts? Many Missions of the Annual MeetingJune 2019
- ASCO Afterthoughts? Many Missions of the Annual MeetingJune 2019
Grant Support
- Genetic Events In The Development Of Renal Cell CarcinomaNational Cancer Institute2007–2011
- Functional And Tissue Specific Effects Of VHL MutationsNational Cancer Institute2003–2007
- Dendritic Cell Vaccine (Mb-002) To Patients With Metastatic Renal Cell CarcinomaNational Center For Research Resources2006
- Calgb 90206: Interferon Alfa-2b Or 2B PLUS Bevacizumab In Renal CarcinomaNational Center For Research Resources2006
- Functional And Tissue Specific Effects Of VHL MutationsNational Cancer Institute2003
Professional Memberships
- Member
- Member
External Links
- VUMC Heme Onchttps://medicine.mc.vanderbilt.edu/welcome-division-hematologyoncology
- VICChttp://www.vicc.org/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: